je.st
news
Tag: merck
Merck to Hold Second-Quarter 2013 Sales and Earnings Conference Call on July 30
2013-06-28 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 30. During the call, Kenneth C. Frazier, chairman and chief executive officer; Peter N. Kellogg, executive vice president and chief financial officer; and Adam H. Schechter, president, Global Human Health, will provide an overview of Mercks financial performance for the quarter. Language: English Contact: MerckMedia:Steven Cragle, 908-423-3461orKelley Dougherty, 908-423-4291orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck: Respiratory Medicine Running Out Of Breath
2013-06-26 16:09:16| Biotech - Topix.net
Merck's leading respiratory therapeutic Singulair , a once-a-day oral medicine for the chronic treatment of asthma and for the relief of symptoms of allergic rhinitis which generated more than $44 billion of revenue since its launch in February 1998, lost market exclusivity in the U.S. in August 2012.
Tags: running
medicine
breath
respiratory
Merck KGaA says liquid crystals momentum to slow in second half
2013-06-26 11:54:30| Biotech - Topix.net
Germany's Merck KGaA said growth at its liquid crystals business would slow in the second half as its customers, Asian display panel makers, reduce their inventories.
Diabetes drugs: Merck & Co wins injunction against Indian co
2013-06-25 17:21:37| Biotech - Topix.net
SD, a unit of US drugmaker Merck & Co, said it has won an injunction against India's Aprica Pharmaceuticals and a source said this will stop Aprica launching generic versions of two diabetes drugs in India.
Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines
2013-06-12 14:00:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Associations (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors such as JANUVIA (sitagliptin). Language: English Contact HTML: MerckMedia:Pam Eisele(267) 664-0282orKim Hamilton(908) 391-0131orInvestor:Carol Ferguson(908) 423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: other
profile
review
safety
Sites : [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] next »